XML 9 R3.htm IDEA: XBRL DOCUMENT v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Millions
Mar. 31, 2026
Sep. 30, 2025
Current assets    
Cash and cash equivalents $ 343 $ 215
Accounts receivable, net - Note H [1] 244 242
Inventories - Note F 506 568
Other assets 116 180
Total current assets 1,209 1,205
Property, plant and equipment    
Cost 3,362 3,355
Accumulated depreciation 2,199 2,154
Net property, plant and equipment 1,163 1,201
Goodwill - Note G [2] 700 705
Intangibles - Note G 529 563
Operating lease assets, net - Note I 101 103
Restricted investments - Note E 276 297
Asbestos insurance receivable, net - Note L [3] 122 127
Deferred income taxes 157 157
Other assets 242 253
Total noncurrent assets 3,290 3,406
Total assets 4,499 4,611
Current liabilities    
Trade and other payables 181 189
Accrued expenses and other liabilities 195 213
Current operating lease obligations - Note I 19 21
Total current liabilities 395 423
Noncurrent liabilities    
Long-term debt - Note H 1,374 1,384
Asbestos litigation reserves - Note L 362 389
Deferred income taxes 31 31
Employee benefit obligations - Note K 96 96
Operating lease obligations - Note I 85 85
Other liabilities 290 299
Total noncurrent liabilities 2,238 2,284
Commitments and contingencies - Note I and L
Equity - Note N 1,866 1,904
Total liabilities and equity $ 4,499 $ 4,611
[1] Accounts receivable, net includes an allowance for credit losses of $4 million and $2 million at March 31, 2026 and September 30, 2025, respectively.
[2] As of both March 31, 2026 and September 30, 2025, there were accumulated impairments of $375 million, $356 million, $505 million and $90 million related to the Life Sciences, Personal Care, Specialty Additives and Intermediates reportable segments, respectively.
[3] Asbestos insurance receivable, net includes an allowance for credit losses of $2 million at both March 31, 2026 and September 30, 2025.